Drugs and patents in ATC class C05AA

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ACETASOL HC	acetic acid, glacial; hydrocortisone
ACETIC ACID W/ HYDROCORTISONE	acetic acid, glacial; hydrocortisone
HYDROCORTISONE AND ACETIC ACID	acetic acid, glacial; hydrocortisone
>Tradename	>Generic Name

Last updated: August 1, 2026

ATC Class C05AA covers corticosteroids used primarily in topical anorectal medicines, including hydrocortisone, prednisolone, fluocortolone, fluocortin, beclometasone and related agents. The class is mature, largely genericized and dominated by low-cost creams, ointments, suppositories and combination products. Market barriers now arise mainly from formulation know-how, regulatory status, manufacturing controls and brand distribution rather than unexpired active-ingredient patents.

What drugs are included in ATC Class C05AA?

C05AA is the ATC category for corticosteroids used in preparations for hemorrhoids and other anorectal conditions. Products may contain a corticosteroid alone or combine it with a local anesthetic, astringent, antimicrobial or other active ingredient.

C05AA active ingredient or group	Common dosage forms	Typical use
Hydrocortisone	Cream, ointment, suppository, foam	Hemorrhoids, anorectal inflammation and itching
Hydrocortisone acetate	Cream, ointment, suppository	Local anti-inflammatory treatment
Prednisolone	Ointment, suppository, cream	Inflammatory anorectal disorders
Fluocortolone	Ointment, suppository, cream	Hemorrhoids and proctitis
Fluocortin	Topical preparations	Local inflammatory conditions
Beclometasone	Cream, ointment, suppository	Anorectal inflammation in selected markets
Other topical corticosteroids	Creams, ointments and combination products	Market-specific anorectal indications

The ATC classification is therapeutic, not a patent or regulatory classification. A product can fall within C05AA while being regulated as a prescription medicine, over-the-counter medicine or traditional market-specific product.

How large is the C05AA market?

The C05AA market is fragmented and difficult to measure as a single global category because products are sold through prescription, pharmacy and consumer-health channels. Revenue is concentrated in branded combinations and established regional products, while unit volume is spread across generic hydrocortisone products.

What drives demand for topical anorectal corticosteroids?

Demand is linked to:

Hemorrhoids and anal fissure symptoms.
Short-term treatment of itching, swelling and inflammation.
Chronic inflammatory anorectal disease, including selected proctitis indications.
Aging populations and constipation-related conditions.
Self-care purchases in countries permitting nonprescription hydrocortisone.
Physician preference for combination products containing anesthetics or protectants.

Products generally compete on symptom relief, ease of application, package size, applicator design, tolerability and pharmacy availability. Active-ingredient differentiation is limited.

How do branded and generic products compete?

Generic hydrocortisone and hydrocortisone acetate products usually compete on price. Branded products retain share through:

Combination formulations.
Suppository or foam delivery.
Brand recognition in hemorrhoid treatment.
Consumer advertising.
Retail distribution.
Applicator and packaging convenience.
Physician familiarity with regional products.

The most defensible commercial positions are usually held by products with a distinctive dosage form, a regulated combination, an established brand or a distribution advantage.

What patents protect C05AA corticosteroid products?

Most core C05AA active ingredients entered the market decades ago. Composition-of-matter patents for hydrocortisone, prednisolone, beclometasone and related corticosteroids have expired in major jurisdictions.

The remaining patent activity generally concerns:

Formulations
Cream bases, ointments, emulsions, foams, gels, suppositories and controlled-release vehicles.
Combination products
Corticosteroid combinations with anesthetics such as lidocaine, protectants, astringents, antimicrobials or vasoconstrictors.
Delivery systems
Metered-dose rectal foams, applicators, single-dose devices and low-mess delivery systems.
Manufacturing processes
Particle-size control, suspension stability, homogeneity, suppository molding, preservative systems and filling processes.
Method-of-use claims
Dosing frequency, treatment duration, symptom-specific use and administration techniques.
Packaging and device claims
Applicator geometry, dose metering, protective caps and packaging that limits contamination.

How strong is the patent estate for C05AA corticosteroids?

The estate is weak for the underlying molecules and stronger for selected products with proprietary dosage forms or combinations.

Patent layer	Typical status	Commercial significance
Active-ingredient patent	Expired	Little or no exclusivity
Basic topical formulation	Usually expired or vulnerable	Limited barrier
Combination formulation	Product-specific	Moderate barrier where claims are narrow
Rectal foam or metered delivery	May remain protected for newer products	Higher risk for direct substitutes
Manufacturing process	Often difficult to detect from public labels	Can delay technically complex launches
Method of use	Generally narrow	Depends on label and infringement theory
Device or applicator	Product-specific	Can support differentiation but rarely blocks all entry

Patent strength depends on claim scope, written-description support, prosecution history, freedom-to-operate around excipients and the availability of alternative formulations. A patent covering one cream base normally does not block a generic ointment or suppository unless the claims extend to the broader dosage form.

What is the Orange Book status of C05AA products?

The FDA Orange Book does not classify products by ATC code. Orange Book listings depend on the individual U.S. drug product, its application type and whether the product is approved under an abbreviated new drug application or a full new drug application.

U.S. hydrocortisone anorectal products may fall into different regulatory categories:

Prescription products approved under an NDA.
Generic products approved under an ANDA.
OTC products marketed under the FDA monograph system.
Products marketed under older regulatory pathways or with limited current approval data.

The FDA OTC monograph for anorectal drug products establishes conditions for certain active ingredients, including hydrocortisone, concentrations, dosage forms and labeling requirements. Products that conform to the applicable monograph generally do not rely on a listed patent for market access.

Does an Orange Book listing create a major barrier?

Usually not for established C05AA products. A listed formulation or method-of-use patent can trigger a Paragraph IV dispute, but many hydrocortisone anorectal products have no commercially meaningful remaining patent protection.

A company evaluating entry must distinguish:

A listed patent from an unlisted formulation patent.
An approved prescription product from a monograph OTC product.
An NDA product from a pharmacy-compounded preparation.
Patent expiry from regulatory exclusivity expiry.
A product-specific patent from broad freedom to market the active ingredient.

When does C05AA corticosteroid exclusivity expire?

Core molecular exclusivity has already expired for the principal C05AA corticosteroids. Current exclusivity depends on the specific product and jurisdiction.

Exclusivity type	Current relevance
Composition-of-matter exclusivity	Generally expired
U.S. five-year new chemical entity exclusivity	Not relevant to historic C05AA molecules
Three-year clinical-investigation exclusivity	Possible only for qualifying later approvals
Orphan exclusivity	Generally not central to ordinary hemorrhoid products
Pediatric exclusivity	Product-specific and uncommon in this category
Formulation patent term	Potentially relevant for newer foam or delivery systems
OTC monograph protection	Regulatory status, not patent exclusivity

Patent term adjustments and patent term extensions can affect individual products, but they are unlikely to restore exclusivity to the historic C05AA molecules.

Which companies are challenging C05AA products?

Competition is usually dispersed among generic manufacturers, contract manufacturers and regional consumer-health companies rather than concentrated in a small group of Paragraph IV challengers.

Relevant participant types include:

Large generic companies producing hydrocortisone creams, ointments and suppositories.
Regional manufacturers of fluocortolone and prednisolone products.
Consumer-health companies selling nonprescription hemorrhoid products.
Specialty companies developing rectal foams and applicator-based products.
Contract development and manufacturing organizations producing semisolids and suppositories.

Public Paragraph IV activity is less visible than in high-value oral or injectable products because C05AA products typically have lower sales potential and limited remaining patent duration. A challenger can often enter through a non-infringing formulation, a monograph route or a different dosage form.

What formulation patents protect topical anorectal corticosteroids?

Creams and ointments

Formulation claims may cover:

Emulsion type.
Oil-to-water ratio.
Suspending agents.
Preservative systems.
Viscosity.
Skin or mucosal adhesion.
Reduced irritation.
Improved corticosteroid dispersion.

These patents can have practical value when the branded product has a commercially recognized texture or tolerability profile. They rarely protect the entire therapeutic category.

Suppositories

Suppository patents may address:

Base composition.
Melting or softening point.
Drug uniformity.
Release rate.
Manufacturing temperature.
Stability during storage.
Single-dose packaging.

A generic suppository manufacturer can sometimes avoid claims by changing the base, excipient ratio or manufacturing process.

Rectal foams

Foam products have a stronger technical barrier than simple creams because development requires control of:

Foam density.
Droplet or particle distribution.
Propellant selection.
Valve performance.
Dose uniformity.
Actuator and applicator design.
Stability after repeated use.

Foam patents can create a more meaningful entry barrier, although alternative aerosol systems may be possible.

What patent litigation affects C05AA corticosteroids?

C05AA litigation is generally less extensive than litigation involving high-revenue systemic corticosteroids. Disputes tend to involve:

ANDA infringement claims for branded prescription products.
Formulation patents for foams, creams or suppositories.
Trade-secret claims involving manufacturing processes.
Trademark and trade-dress disputes for OTC products.
Regulatory disputes over whether a product falls within the OTC monograph.
Patent ownership or licensing disputes involving regional brands.

The litigation value of a C05AA patent depends on product revenue. A narrow formulation patent may support settlement leverage but may not justify prolonged litigation if a challenger can launch an alternative dosage form.

Are there biosimilar risks for C05AA corticosteroids?

There is no material biosimilar risk for traditional C05AA corticosteroids because the active ingredients are small-molecule chemicals, not biologics. The relevant competitive threats are:

ANDA-approved generics.
OTC monograph products.
Authorized generics.
Regional prescription products.
Pharmacy-compounded preparations.
Alternative dosage forms.

Regulatory review focuses on pharmaceutical equivalence, bioequivalence where applicable, formulation quality and local tolerability rather than biosimilarity.

What generic entry risks exist for C05AA products?

Generic entry risk is high for conventional hydrocortisone creams, ointments and suppositories. It is more moderate for products requiring specialized delivery technology.

Product type	Generic entry risk	Main barrier
Hydrocortisone cream	High	Low technical complexity
Hydrocortisone ointment	High	Established excipient alternatives
Hydrocortisone suppository	Moderate to high	Base and manufacturing controls
Combination cream	Moderate	Combination equivalence and formulation claims
Rectal foam	Moderate	Device, propellant and dose uniformity
Branded applicator product	Moderate	Device and packaging differentiation
Specialty low-irritation formulation	Moderate	Formulation development and clinical positioning

The most likely launch route for a competitor is a conventional generic cream or ointment. A company seeking premium pricing would need a differentiated foam, delivery device, tolerability profile or combination indication.

How do C05AA products compare across geographic markets?

United States

The market is divided between OTC monograph products and prescription products. Hydrocortisone is widely available, while prescription combinations and specialized dosage forms may have separate approval requirements. Orange Book analysis must be performed product by product.

European Union

National authorization and mutual-recognition structures create a fragmented commercial environment. Fluocortolone and related combination products have stronger positions in some European markets than in the United States. Patent expiry is usually less important than national reimbursement, pharmacy substitution and marketing authorization status.

Japan

Regulatory classification, prescribing practices and local product histories influence competition. Established topical products may retain commercial value despite expired patents through physician familiarity and distribution.

Emerging markets

Local manufacturers often compete with low-cost creams and ointments. Regulatory enforcement, trademark protection, manufacturing quality and channel access can be more important than patent rights.

What licensing deals affect the C05AA market?

Licensing activity is usually product-specific and private. Common arrangements include:

Regional licensing of established hemorrhoid brands.
Contract manufacturing agreements for semisolid products.
Technology licenses for rectal foams and applicators.
Private-label supply agreements with retailers.
Transfers of marketing authorizations between specialty and consumer-health companies.

Because the underlying molecules are off patent, deal value generally depends on brand rights, regulatory approvals, manufacturing capacity and distribution rather than molecule ownership.

What manufacturing and IP barriers matter most?

Manufacturing capability is a meaningful barrier for companies entering with a differentiated C05AA product. Key capabilities include:

Semisolid mixing under controlled temperature and shear.
Uniform corticosteroid dispersion.
Microbiological control.
Preservative validation.
Suppository filling and molding.
Aerosol filling for rectal foams.
Applicator assembly and dose consistency.
Stability testing under hot and humid conditions.

Manufacturing know-how may remain commercially valuable even when patents have expired. Trade secrets can protect process parameters, but they do not prevent independent development.

What are the likely generic launch scenarios?

Conventional cream or ointment

This is the most probable low-cost entry scenario. Competition can begin after approval or monograph compliance, with limited litigation exposure.

Alternative dosage form

A competitor may enter with a suppository, foam or different vehicle to avoid formulation claims. This can reduce direct substitutability but also lowers development risk from narrow patent claims.

Paragraph IV launch

A Paragraph IV strategy is most relevant when a branded prescription product has listed formulation or method-of-use patents and enough sales to justify litigation. The challenger may assert invalidity, non-infringement or lack of enforceability.

Authorized generic

A branded manufacturer may launch or license an authorized generic to preserve channel access and reduce the price gap after generic approval.

OTC conversion or monograph entry

Where the active ingredient, concentration, indication and dosage form comply with the FDA monograph, OTC entry can bypass much of the patent-centered approval process.

What is the commercial outlook for C05AA corticosteroids?

The outlook is stable in volume and limited in patent-driven pricing power. Growth is more likely to come from:

OTC self-care expansion.
Premium foam and applicator products.
Combination products.
Regional brand acquisitions.
Retail pharmacy distribution.
Reformulations designed to reduce mess and improve adherence.

Revenue exposure for incumbent manufacturers is concentrated in brands with differentiated delivery, strong retail placement or prescription status. Conventional hydrocortisone products face persistent price erosion and substitution.

Key Takeaways

C05AA covers topical anorectal corticosteroids, not systemic corticosteroid products.
The core molecules are off patent in major markets.
Hydrocortisone creams, ointments and suppositories face high generic entry risk.
Rectal foams, applicators and complex combinations have stronger formulation and manufacturing barriers.
Orange Book status must be assessed at the individual U.S. product level.
Paragraph IV litigation is possible but less common than in higher-value drug categories.
Biosimilar risk is not relevant because C05AA products are small molecules.
Commercial value depends on brand, formulation, device, regulatory pathway and distribution.
Patent protection is generally narrow and product-specific.
Generic entry is most likely through a conventional cream or ointment, an alternative dosage form or OTC monograph compliance.

FAQs

Are hydrocortisone hemorrhoid products still patent protected?

The hydrocortisone molecule and historic basic formulations are generally off patent. Product-specific formulation, device or method-of-use patents may still require review.

Does C05AA include oral or injectable corticosteroids?

No. C05AA is an anorectal therapeutic category. Oral and injectable corticosteroids fall into different ATC classifications.

Can a company launch a generic C05AA cream without a Paragraph IV filing?

Yes, depending on the regulatory pathway and the reference product. An OTC monograph-compliant product may not require an ANDA or Paragraph IV certification.

Are fluocortolone products protected by active-ingredient patents?

Historic fluocortolone active-ingredient patents have expired. Remaining barriers, where present, are more likely to involve formulations, combinations, trademarks or local regulatory rights.

What is the strongest patent opportunity in C05AA?

The strongest opportunities are generally in rectal foams, metered delivery systems, stable combination formulations and applicator technologies rather than in the corticosteroid active ingredients.

References

European Medicines Agency. (n.d.). European public assessment reports and medicines database. https://www.ema.europa.eu/
Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
Food and Drug Administration. (n.d.). Code of Federal Regulations, Title 21, Part 346: Anorectal drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-346
World Health Organization Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC/DDD index: C05AA corticosteroids. https://atcddd.fhi.no/atc_ddd_index/
U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search. https://www.uspto.gov/patents/search